Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Net margin is calculated as Net Income divided by its Revenue. Mycenax Biotech's Net Income for the
three
months ended in Dec. 2025 was NT$-52.4 Mil. Mycenax Biotech's Revenue for the
three
months ended in Dec. 2025 was NT$284.6 Mil. Therefore, Mycenax Biotech's net margin for the quarter that ended in Dec. 2025 was -18.43%.
The historical rank and industry rank for Mycenax Biotech's Net Margin % or its related term are showing as below:
ROCO:4726'
s Net Margin % Range Over the Past 10 Years
Min: -129.8 Med: -61.28 Max: 4.65
Current: -60.61
ROCO:4726's Net Margin % is ranked better than 53.03% of 941
companies
in the Biotechnology industry
Industry Median: -88.29
vs ROCO:4726: -60.61
Mycenax Biotech (ROCO:4726) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Mycenax Biotech Net Margin % Related Terms
Mycenax Biotech Net Margin % Historical Data
* Premium members only.
The historical data trend for Mycenax Biotech's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4726 vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Mycenax Biotech's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mycenax Biotech Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mycenax Biotech's Net Margin % distribution charts can be found below:
* The bar in red indicates where Mycenax Biotech's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mycenax Biotech (ROCO:4726) has a Net Margin % of -18.43% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Mycenax Biotech and its competitors. According to the industry distribution chart, Mycenax Biotech ranks #442 out of 941 companies in the Biotechnology industry, placing it in the top 47%.
Is Mycenax Biotech's Net Margin % too high?
Mycenax Biotech's current Net Margin % is -18.43%. Based on the distribution chart, Mycenax Biotech ranks #442 out of 941 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Mycenax Biotech has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mycenax Biotech's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Mycenax Biotech ranks #442 out of 941 companies for Net Margin %. This puts Mycenax Biotech in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Mycenax Biotech and its competitors. Mycenax Biotech's current Net Margin % is -18.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mycenax Biotech stock overvalued right now?
Based on GuruFocus' analysis, Mycenax Biotech (ROCO:4726) is currently considered Possible Value Trap. The stock's GF Value™ is NT$47.88, compared to a current price of NT$24.50 — trading 48.8% below its estimated fair value. The current Net Margin % is -18.43%. Mycenax Biotech's overall GF Score™ is 43/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Mycenax Biotech (ROCO:4726), the current Net Margin % is -18.43% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mycenax Biotech (ROCO:4726) Overvalued in 2026?
Based on GuruFocus' analysis, Mycenax Biotech stock appears to be undervalued.
The current stock price of NT$24.50 is trading 48.8% below its estimated GF Value™ of NT$47.88.
GuruFocus considers Mycenax Biotech to be Possible Value Trap.
Key valuation signals for ROCO:4726:
Net Margin %: -18.43%
GF Value™: NT$47.88 vs. price of NT$24.50 (48.8% below fair value)
No single metric tells the full story. See the ROCO:4726 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mycenax Biotech Inc is a Taiwan-based biopharmaceutical company. It is engaged in the development and manufacture of biopharmaceutical products, specializing in mammalian and microbial cell-derived biologics. The company provides services for program evaluation/confirmation, cell line development, and construction, process development technology platforms, drug characterization analysis, the establishment of testing methods, and drug production in accordance with PIC/S GMP manufacturing standards. The company's main operating region is located in Taiwan.
43GF Score
Get the complete analysis for ROCO:4726
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4726 has been successfully added to your 
